DACOMITINIB

Details

Stereochemistry	ACHIRAL
Molecular Formula	C24H25ClFN5O2.H2O
Molecular Weight	487.954
Optical Activity	NONE
Defined Stereocenters	0 / 0
E/Z Centers	1
Charge	0

SHOW SMILES / InChI

Structure Search

SMILES

O.COC1=C(NC(=O)\C=C\CN2CCCCC2)C=C3C(NC4=CC=C(F)C(Cl)=C4)=NC=NC3=C1

InChI

InChIKey=BSPLGGCPNTZPIH-IPZCTEOASA-N

InChI=1S/C24H25ClFN5O2.H2O/c1-33-22-14-20-17(24(28-15-27-20)29-16-7-8-19(26)18(25)12-16)13-21(22)30-23(32)6-5-11-31-9-3-2-4-10-31;/h5-8,12-15H,2-4,9-11H2,1H3,(H,30,32)(H,27,28,29);1H2/b6-5+;

HIDE SMILES / InChI

Molecular Formula	H2O
Molecular Weight	18.0153
Charge	0
Count

Stereochemistry	ACHIRAL
Additional Stereochemistry	No
Defined Stereocenters	0 / 0
E/Z Centers	0
Optical Activity	NONE

Molecular Formula	C24H25ClFN5O2
Molecular Weight	469.939
Charge	0
Count

Stereochemistry	ACHIRAL
Additional Stereochemistry	No
Defined Stereocenters	0 / 0
E/Z Centers	1
Optical Activity	NONE

Description
Sources: https://www.pfizer.com/files/news/esmo/dacomitinib_fact_sheet.pdf
Curator's Comment: description was created based on several sources, including https://www.ncbi.nlm.nih.gov/pubmed/26768165 | http://www.ncbi.nlm.nih.gov/pubmed/22761403 | https://www.ncbi.nlm.nih.gov/pubmed/25939761

Dacomitinib is an oral, once-daily, pan-HER inhibitor. It is an irreversible inhibitor of HER-1 (EGFR), HER-2 and HER-4 tyrosine kinases. Dacomtinib is being evaluated in phase 3 clinical trials against nonsmall-cell lung cancer. Direct comparison with erlotinib did not show superiority of dacomtinib, but subgroup analysis have demonstrated that subgroup with exon 19 deletion had favorable outcomes with dacomitinib. In addition to nonsmall-cell lung cancer dacomtinib is being evaluated against esophagus, head and neck and other neoplasms. Due to its ability to pass through blood-brain barrier, dacomitinib can be used to treat brain tumors.

CNS Activity

Originator

Approval Year

Targets

Primary Target	Pharmacology	Potency
Epidermal growth factor receptor erbB1 58 Target ID: CHEMBL203 Sources: http://www.ncbi.nlm.nih.gov/pubmed/22761403	Inhibitor 8297	6.0 nM [IC50]
Receptor protein-tyrosine kinase erbB-2 35 Target ID: CHEMBL1824 Sources: http://www.ncbi.nlm.nih.gov/pubmed/22761403	Inhibitor 8297	45.7 nM [IC50]
Receptor protein-tyrosine kinase erbB-4 12 Target ID: CHEMBL3009 Sources: http://www.ncbi.nlm.nih.gov/pubmed/22761403	Inhibitor 8297	73.7 nM [IC50]

Conditions

Condition	Modality	Highest Phase	Product
Non-small cell lung cancer 206 Sources: https://www.accessdata.fda.gov/drugsatfda_docs/label/2018/211288s000lbl.pdf	Primary	Approved 8429	VIZIMPRO Approved Use VIZIMPRO is a kinase inhibitor indicated for the first-line treatment of patients with metastatic non-small cell lung cancer (NSCLC) with epidermal growth factor receptor (EGFR) exon 19 deletion or exon 21 L858R substitution mutations as detected by an FDA-approved test. Launch Date 2018
Esophageal squamous cell carcinoma 2 Sources: https://www.ncbi.nlm.nih.gov/pubmed/26462025	Primary	Phase II 1132	Unknown Approved Use Unknown
Head and neck squamous cell carcinoma 32 Sources: https://www.ncbi.nlm.nih.gov/pubmed/25424851	Primary	Phase II 1132	Unknown Approved Use Unknown
Glioblastoma 65 Sources: https://clinicaltrials.gov/ct2/show/NCT01112527	Primary	Phase II 1132	Unknown Approved Use Unknown

C_max

Value	Dose	Co-administered	Analyte	Population
108 ng/mL DRUG LABEL https://www.accessdata.fda.gov/drugsatfda_docs/label/2018/211288s000lbl.pdf	45 mg 1 times / day steady-state, oral dose: 45 mg route of administration: Oral experiment type: STEADY-STATE co-administered:		DACOMITINIB plasma	Homo sapiens population: UNHEALTHY age: ADULT sex: UNKNOWN food status: UNKNOWN
105 ng/mL DRUG LABEL https://www.accessdata.fda.gov/drugsatfda_docs/nda/2018/211288Orig1s000MultidisciplineR.pdf	60 mg 1 times / day steady-state, oral dose: 60 mg route of administration: Oral experiment type: STEADY-STATE co-administered:		DACOMITINIB unknown	Homo sapiens population: UNHEALTHY age: ADULT sex: UNKNOWN food status: UNKNOWN

AUC

Value	Dose	Co-administered	Analyte	Population
2213 ng × h/mL DRUG LABEL https://www.accessdata.fda.gov/drugsatfda_docs/label/2018/211288s000lbl.pdf	45 mg 1 times / day steady-state, oral dose: 45 mg route of administration: Oral experiment type: STEADY-STATE co-administered:		DACOMITINIB plasma	Homo sapiens population: UNHEALTHY age: ADULT sex: UNKNOWN food status: UNKNOWN
1720 ng × h/mL DRUG LABEL https://www.accessdata.fda.gov/drugsatfda_docs/nda/2018/211288Orig1s000MultidisciplineR.pdf	60 mg 1 times / day steady-state, oral dose: 60 mg route of administration: Oral experiment type: STEADY-STATE co-administered:		DACOMITINIB unknown	Homo sapiens population: UNHEALTHY age: ADULT sex: UNKNOWN food status: UNKNOWN

T_1/2

Value	Dose	Co-administered	Analyte	Population
70 h DRUG LABEL https://www.accessdata.fda.gov/drugsatfda_docs/label/2018/211288s000lbl.pdf	45 mg 1 times / day steady-state, oral dose: 45 mg route of administration: Oral experiment type: STEADY-STATE co-administered:		DACOMITINIB plasma	Homo sapiens population: UNHEALTHY age: ADULT sex: UNKNOWN food status: UNKNOWN

F_unbound

Value	Dose	Co-administered	Analyte	Population
2% DRUG LABEL https://www.accessdata.fda.gov/drugsatfda_docs/label/2018/211288s000lbl.pdf	45 mg 1 times / day steady-state, oral dose: 45 mg route of administration: Oral experiment type: STEADY-STATE co-administered:		DACOMITINIB plasma	Homo sapiens population: UNHEALTHY age: ADULT sex: UNKNOWN food status: UNKNOWN

Doses

Dose	Population	Adverse events
45 mg 1 times / day multiple, oral MTD Dose: 45 mg, 1 times / day Route: oral Route: multiple Dose: 45 mg, 1 times / day Sources: https://www.accessdata.fda.gov/drugsatfda_docs/label/2018/211288s000lbl.pdf	unhealthy n = 227 Health Status: unhealthy Condition: non-small cell lung cancer Population Size: 227 Sources: https://www.accessdata.fda.gov/drugsatfda_docs/label/2018/211288s000lbl.pdf	Other AEs: Diarrhea, Diarrhea... Other AEs: Diarrhea (grade 1-2, 79%) Diarrhea (grade 3-4, 8%) Mucosal inflammation (grade 1-2, 40.6%) Stomatitis (grade 1-2, 40.6%) Mucosal inflammation (grade 3-4, 4.4%) Stomatitis (grade 3-4, 4.4%) Nausea (grade 1-2, 17.7%) Nausea (grade 3-4, 1.3%) Constipation (grade 1-2, 13%) Mouth ulceration (grade 1-2, 12%) Dermatitis acneiform (grade 1-2, 46%) Rash (grade 1-2, 46%) Rash maculo-papular (grade 1-2, 46%) Dermatitis acneiform (grade 3-4, 23%) Rash (grade 3-4, 23%) Rash maculo-papular (grade 3-4, 23%) Nail infection (grade 1-2, 56%) Nail toxicity (grade 1-2, 56%) Onychoclasis (grade 1-2, 56%) Onycholysis (grade 1-2, 56%) Onychomadesis (grade 1-2, 56%) Paronychia (grade 1-2, 56%) Nail infection (grade 3-4, 8%) Nail toxicity (grade 3-4, 8%) Onychoclasis (grade 3-4, 8%) Onycholysis (grade 3-4, 8%) Onychomadesis (grade 3-4, 8%) Paronychia (grade 3-4, 8%) Dry skin (grade 1-2, 28.2%) Xerosis (grade 1-2, 28.2%) Dry skin (grade 3-4, 1.8%) Xerosis (grade 3-4, 1.8%) Alopecia (grade 1-2, 22.6%) Alopecia (grade 3-4, 0.4%) Pruritus (grade 1-2, 20.1%) Pruritus generalized (grade 1-2, 20.1%) Rash pruritic (grade 1-2, 20.1%) Pruritus (grade 3-4, 0.9%) Pruritus generalized (grade 3-4, 0.9%) Rash pruritic (grade 3-4, 0.9%) Palmar-plantar erythrodysesthesia syndrome (grade 1-2, 14.1%) Palmar-plantar erythrodysesthesia syndrome (grade 3-4, 0.9%) Dermatitis (grade 1-2, 9.2%) Dermatitis (grade 3-4, 1.8%) Decreased appetite (grade 1-2, 27.9%) Decreased appetite (grade 3-4, 3.1%) Weight decreased (grade 1-2, 23.8%) Weight decreased (grade 3-4, 2.2%) Cough (grade 1-2, 21%) Epistaxis (grade 1-2, 19%) Nasal inflammation (grade 1-2, 19%) Nasal mucosal disorder (grade 1-2, 19%) Nasal mucosal ulcer (grade 1-2, 19%) Rhinitis (grade 1-2, 19%) Dyspnea (grade 1-2, 10.8%) Dyspnea (grade 3-4, 2.2%) Upper respiratory tract infection (grade 1-2, 10.7%) Upper respiratory tract infection (grade 3-4, 1.3%) Chest pain (grade 1-2, 10%) Conjunctivitis (grade 1-2, 19%) Pain in extremity (grade 1-2, 14%) Musculoskeletal pain (grade 1-2, 11.1%) Musculoskeletal pain (grade 3-4, 0.9%) Asthenia (grade 1-2, 10.8%) Asthenia (grade 3-4, 2.2%) Insomnia (grade 1-2, 10.6%) Insomnia (grade 3-4, 0.4%) Fatigue (all grades, 9%) Skin fissures (all grades, 9%) Hypertrichosis (all grades, 1.3%) Skin exfoliation (all grades, 3.5%) Vomiting (all grades, 9%) Dysgeusia (all grades, 7%) Interstitial lung disease (all grades, 2.6%) Keratitis (all grades, 1.8%) Dehydration (all grades, 1.3%) Anemia (grade 1-2, 43.1%) Anemia (grade 3-4, 0.9%) Lymphopenia (grade 1-2, 36%) Lymphopenia (grade 3-4, 6%) Hypoalbuminemia (grade 1-2, 44%) ALT increased (grade 1-2, 38.6%) ALT increased (grade 3-4, 1.4%) Hyperglycemia (grade 1-2, 35%) Hyperglycemia (grade 3-4, 1%) AST increased (grade 1-2, 34.5%) AST increased (grade 3-4, 0.5%) Hypocalcemia (grade 1-2, 31.6%) Hypocalcemia (grade 3-4, 1.4%) Hypokalemia (grade 1-2, 22%) Hypokalemia (grade 3-4, 7%) Hyponatremia (grade 1-2, 23.1%) Hyponatremia (grade 3-4, 2.9%) Creatinine increased (grade 1-2, 24%) Alkaline phosphatase increased (grade 1-2, 21.5%) Alkaline phosphatase increased (grade 3-4, 0.5%) Hypomagnesemia (grade 1-2, 21.5%) Hypomagnesemia (grade 3-4, 0.5%) Hyperbilirubinemia (grade 1-2, 15.5%) Hyperbilirubinemia (grade 3-4, 0.5%) Sources: https://www.accessdata.fda.gov/drugsatfda_docs/label/2018/211288s000lbl.pdf
45 mg 1 times / day multiple, oral MTD Dose: 45 mg, 1 times / day Route: oral Route: multiple Dose: 45 mg, 1 times / day Sources: https://www.accessdata.fda.gov/drugsatfda_docs/nda/2018/211288Orig1s000MultidisciplineR.pdf	unhealthy n = 227 Health Status: unhealthy Condition: non-small cell lung cancer Population Size: 227 Sources: https://www.accessdata.fda.gov/drugsatfda_docs/nda/2018/211288Orig1s000MultidisciplineR.pdf	Disc. AE: Maculopapular rash, Interstitial lung disease... AEs leading to discontinuation/dose reduction: Maculopapular rash (1%) Interstitial lung disease (1%) Pneumonitis (2%) Stomatitis (1%) Diarrhea (1%) Dermatitis acneiform (1%) Bronchopulmonary aspergillosis (0.4%) Cerebral infarction (0.4%) Infection (0.4%) Keratitis (0.4%) Keratolysis exfoliativa acquired (0.4%) Liver injury (0.4%) Lung infection (0.4%) Lymphocyte count decreased (0.4%) Malaise (0.4%) Malnutrition (0.4%) Muscular weakness (0.4%) Respiratory failure (0.4%) Urinary tract infection (0.4%) Sources: https://www.accessdata.fda.gov/drugsatfda_docs/nda/2018/211288Orig1s000MultidisciplineR.pdf
60 mg 1 times / day steady, oral Dose: 60 mg, 1 times / day Route: oral Route: steady Dose: 60 mg, 1 times / day Sources: https://www.accessdata.fda.gov/drugsatfda_docs/nda/2018/211288Orig1s000MultidisciplineR.pdf	unhealthy Health Status: unhealthy Condition: advanced solid tumors Sources: https://www.accessdata.fda.gov/drugsatfda_docs/nda/2018/211288Orig1s000MultidisciplineR.pdf	Sources: https://www.accessdata.fda.gov/drugsatfda_docs/nda/2018/211288Orig1s000MultidisciplineR.pdf

AEs

Overview

CYP3A4	CYP2C9	CYP2D6	hERG
substrate 1737 inducer 781	inhibitor 1767	substrate 1217 inhibitor 1852	inhibitor 1612

OverviewOther

Other Inhibitor	Other Substrate	Other Inducer
CYP1A2 1524 CYP2B6 810 CYP2C8 911 CYP2C19 1478 CYP3A4/5 278 UGT1A1 204 UGT1A4 77 UGT1A6 108 UGT1A9 116 UGT2B7 146 UGT2B15 64 P-gp 1461 BCRP 699 OCT1 512 OAT1 599 OAT3 642 OCT2 647 OATP1B1 788 OATP1B3 706 BSEP 402	P-gp 1537 BCRP 561	CYP1A2 701 CYP2B6 547

Drug as perpetrator

Target	Modality	Activity	Clinical evidence
BSEP 403	inhibitor 3277 Sources: https://www.accessdata.fda.gov/drugsatfda_docs/nda/2018/211288Orig1s000MultidisciplineR.pdf Page: 61.0	no
CYP1A2 1692	inducer 1573 Sources: https://www.accessdata.fda.gov/drugsatfda_docs/label/2018/211288s000lbl.pdf Page: 13.0	no
CYP1A2 1692	inhibitor 3277 Sources: https://www.accessdata.fda.gov/drugsatfda_docs/label/2018/211288s000lbl.pdf Page: 13.0	no
CYP2B6 1001	inducer 1573 Sources: https://www.accessdata.fda.gov/drugsatfda_docs/label/2018/211288s000lbl.pdf Page: 13.0	no
CYP2B6 1001	inhibitor 3277 Sources: https://www.accessdata.fda.gov/drugsatfda_docs/label/2018/211288s000lbl.pdf Page: 13.0	no
CYP2C19 1553	inhibitor 3277 Sources: https://www.accessdata.fda.gov/drugsatfda_docs/label/2018/211288s000lbl.pdf Page: 13.0	no
CYP2C8 965	inhibitor 3277 Sources: https://www.accessdata.fda.gov/drugsatfda_docs/label/2018/211288s000lbl.pdf Page: 13.0	no
CYP2C9 1819	inhibitor 3277 Sources: https://www.accessdata.fda.gov/drugsatfda_docs/label/2018/211288s000lbl.pdf Page: 13.0	no
CYP3A4 1925	inducer 1573 Sources: https://www.accessdata.fda.gov/drugsatfda_docs/label/2018/211288s000lbl.pdf Page: 13.0	no
CYP3A4/5 335	inhibitor 3277 Sources: https://www.accessdata.fda.gov/drugsatfda_docs/label/2018/211288s000lbl.pdf Page: 13.0	no
OAT1 603	inhibitor 3277 Sources: https://www.accessdata.fda.gov/drugsatfda_docs/label/2018/211288s000lbl.pdf Page: 13.0	no
OAT3 644	inhibitor 3277 Sources: https://www.accessdata.fda.gov/drugsatfda_docs/label/2018/211288s000lbl.pdf Page: 13.0	no
OATP1B1 803	inhibitor 3277 Sources: https://www.accessdata.fda.gov/drugsatfda_docs/label/2018/211288s000lbl.pdf Page: 13.0	no
OATP1B3 715	inhibitor 3277 Sources: https://www.accessdata.fda.gov/drugsatfda_docs/label/2018/211288s000lbl.pdf Page: 13.0	no
OCT2 648	inhibitor 3277 Sources: https://www.accessdata.fda.gov/drugsatfda_docs/label/2018/211288s000lbl.pdf Page: 13.0	no
UGT1A4 80	inhibitor 3277 Sources: https://www.accessdata.fda.gov/drugsatfda_docs/label/2018/211288s000lbl.pdf Page: 13.0	no
UGT1A6 141	inhibitor 3277 Sources: https://www.accessdata.fda.gov/drugsatfda_docs/label/2018/211288s000lbl.pdf Page: 13.0	no
UGT1A9 121	inhibitor 3277 Sources: https://www.accessdata.fda.gov/drugsatfda_docs/label/2018/211288s000lbl.pdf Page: 13.0	no
UGT2B15 64	inhibitor 3277 Sources: https://www.accessdata.fda.gov/drugsatfda_docs/label/2018/211288s000lbl.pdf Page: 13.0	no
UGT2B7 157	inhibitor 3277 Sources: https://www.accessdata.fda.gov/drugsatfda_docs/label/2018/211288s000lbl.pdf Page: 13.0	no
BCRP 773	inhibitor 3277 Sources: https://www.accessdata.fda.gov/drugsatfda_docs/nda/2018/211288Orig1s000MultidisciplineR.pdf Page: 61.0	yes
OCT1 543	inhibitor 3277 Sources: https://www.accessdata.fda.gov/drugsatfda_docs/label/2018/211288s000lbl.pdf Page: 13.0	yes
P-gp 1650	inhibitor 3277 Sources: https://www.accessdata.fda.gov/drugsatfda_docs/nda/2018/211288Orig1s000MultidisciplineR.pdf Page: 61.0	yes
UGT1A1 254	inhibitor 3277 Sources: https://www.accessdata.fda.gov/drugsatfda_docs/label/2018/211288s000lbl.pdf Page: 13.0	yes
CYP2D6 1891	inhibitor 3277 Sources: https://www.accessdata.fda.gov/drugsatfda_docs/nda/2018/211288Orig1s000MultidisciplineR.pdf Page: 55.0	yes	yes (co-administration study) Comment: dacomitnib increased dextromethorphan AUC by 362% and Cmax by 973% Sources: https://www.accessdata.fda.gov/drugsatfda_docs/nda/2018/211288Orig1s000MultidisciplineR.pdf Page: 55.0

Drug as victim

Target	Modality	Activity	Clinical evidence
BCRP 561	substrate 3367 Sources: https://www.accessdata.fda.gov/drugsatfda_docs/label/2018/211288s000lbl.pdf Page: 13.0	yes
CYP3A4 1737	substrate 3367 Sources: https://www.accessdata.fda.gov/drugsatfda_docs/label/2018/211288s000lbl.pdf Page: 11.0	yes
P-gp 1537	substrate 3367 Sources: https://www.accessdata.fda.gov/drugsatfda_docs/label/2018/211288s000lbl.pdf Page: 13.0	yes
CYP2D6 1217	substrate 3367 Sources: https://www.accessdata.fda.gov/drugsatfda_docs/nda/2018/211288Orig1s000MultidisciplineR.pdf Page: 55.0	yes	no (co-administration study) Comment: paroxetine increased dacaomitnib AUC by 37% Sources: https://www.accessdata.fda.gov/drugsatfda_docs/nda/2018/211288Orig1s000MultidisciplineR.pdf Page: 55.0

Tox targets

Target	Modality	Activity	Metabolite	Clinical evidence
hERG 1647	inhibitor 1626 Sources: https://www.accessdata.fda.gov/drugsatfda_docs/nda/2018/211288Orig1s000MultidisciplineR.pdf Page: 29.0

Sourcing

Vendor/Aggregator	ID	URL
AA Blocks	AA008TCL	https://www.aablocks.com/goods/Goods/detail?id=AA008TCL
AK Scientific, Inc. (AKSCI)	Y0338	http://www.aksci.com/item_detail.php?cat=Y0338
Aaron Chemicals	AR008U4D	http://www.aaronchem.com/1110813-31-4
AbMole Bioscience	M1869	http://www.abmole.com/products/dacomitinib.html
Acadechem	ACDS-068047	http://www.acadechemical.com/product/142746
Aceschem	ACF023368	https://www.aceschem.com/catalog/1110813-31-4.html
Achemtek	0102-012372	http://www.achemtek.com/1110813-31-4
Acorn PharmaTech	ACN-031538	http://www.acornpharmatech.com/
Acorn PharmaTech	ACN-039804	http://www.acornpharmatech.com/
Active Biopharma	ABP000126	http://www.activebiopharma.com/1110813-31-4
Adooq BioScience	PF299804	http://www.adooq.com/pf299804.html
Adooq BioScience	A11051	https://www.adooq.com/pf299804.html
Allbio Pharm Co., Ltd	AF10236	http://www.allbiopharm.com/product/n/AF10236
Alsachim	4710	http://www.alsachim.com/product-C6058-glo.bal-view.html
Ambinter	Amb22170031	http://www.ambinter.com/reference/22170031
ApexBio Technology	A8319	http://www.apexbt.com/dacomitinib-pf299804-pf299.html
Aurora Fine Chemicals LLC	A24.092.577	http://online.aurorafinechemicals.com/info?ID=A24.092.577
Aurora Fine Chemicals LLC	K16.647.345	http://online.aurorafinechemicals.com/info?ID=K16.647.345
Aurum Pharmatech LLC	Q-4059	http://www.Aurumpharmatech.com/Product/ProductDetails/Q_4059
Axon MedChem	3235	https://www.axonmedchem.com/product/3235
BioChemPartner	BCP02530	http://www.biochempartner.com/1110813-31-4-BCP02530
BioCrick	BCC3683	http://www.biocrick.com/Dacomitinib-PF299804-PF299-BCC3683.html
BioSynth	J-500784	https://www.biosynth.com/en/products/all-products/products/J-500784.html
Boerchem	BC261945	http://www.boerchem.com/?product_43053.html
Chem Scene	CS-0500	http://www.chemscene.com/1110813-31-4.html
ChemWise	AR60114	http://www.chemwisellc.com/product/dacomitinib-pf299804/
Chemspace	CSSB00016996156	https://chem-space.com/CSSB00016996156
DC Chemicals	DC1091	http://www.dcchemicals.com/product_show-PF_299804_Dacomitinib_PF_00299804_.html
Excenen	EX-A030	http://www.excenen.com/searchresultlist.php?id=1110813-31-4
Glentham Life Sciences	GP3436	http://www.glentham.com/products/product/GP3436/
Hairui	HR144463	http://www.hairuichem.com/en/product/1110813-31-4.html
Matrix Scientific	125377	https://www.matrixscientific.com/125377.html
MedChem Express	HY-13272	https://www.medchemexpress.com/Dacomitinib.html
Renno Tech	RL00451	http://www.rennotech.com/product_show.asp?id=1197
Sinfoo Biotech	S052390	http://www.sinfoobiotech.com/product/1055788
Smolecule	S547934	http://www.smolecule.com/products/s547934
Smolecule	S785416	https://www.smolecule.com/products/s785416
Synblock Inc	SB21754	http://www.synblock.com/product/1110813-31-4.html
TCI (Tokyo Chemical Industry)	D5450	http://www.tcichemicals.com/eshop/en/us/commodity/D5450/index.html
THE BioTek	bt-287214	https://www.thebiotek.com/product/inhibitors/bt-287214
Tocris	6231	https://www.tocris.com/products/dacomitinib_6231
VladaChem	VL263938-10MG	https://www.vladachem.com/product.php?products=1110813-31-4
Yuhao Chemical	YH65989	http://www.chemyuhao.com/1110813-31-4.html
abcr GmbH	AB447090	http://www.abcr.com/shop/en/AB447090
eNovation Chemicals	K13827	https://www.enovationchem.com/ProductDetails.asp?ProductID=K13827
eNovation Chemicals	Y0974039	https://www.enovationchem.com/ProductDetails.asp?ProductID=Y0974039

PubMed

Title	Date	PubMed
Irreversible protein kinase inhibitors: balancing the benefits and risks.	2012 Jul 26	22621397

Patents

Sample Use Guides

In Vivo Use Guide

In phase III study against non small cell lung cancer dacomitinib was administered orally at a dose 45 mg a day.

Route of Administration: Oral

In Vitro Use Guide

Cells were seeded in duplicate at 5 × 103 to 5 × 104 cells per well in 24-well plates. A day after plating, dacomitinib was added at 10 μmol/L and 2-fold dilutions over 12 concentrations were carried out to generate a dose–response curve. Control wells without the drug were also seeded. The cells were counted on day 1 when the drug was added, as well as after 6 days when the experiment ended. After the trypsinization cells were placed in an Isotone solution and immediately counted using a Coulter Z1 particle counter (Beckman Coulter, Inc.). The suspension cultures were counted using a Coulter Vi-Cell counter (Beckman Coulter, Inc.). As a group, HER2-amplified cell lines were most sensitive to growth inhibition by dacomitinib (IC50 < 1 μmol/L in 14 of 16 lines).

Substance Class	Chemical Created by `admin` on `Fri Dec 15 15:40:47 GMT 2023` Edited by `admin` on `Fri Dec 15 15:40:47 GMT 2023`
Record UNII	5092U85G58
Record Status	`Validated (UNII)`
Record Version

Download

Name

Type

Language

DACOMITINIB

Official Name

English

DACOMITINIB MONOHYDRATE

Common Name

English

DACOMITINIB [USAN]

Common Name

English

DACOMITINIB HYDRATE [JAN]

Common Name

English

DACOMITINIB [ORANGE BOOK]

Common Name

English

2-BUTENAMIDE, N-(4-((3-CHLORO-4-FLUOROPHENYL)AMINO)-7-METHOXY-6-QUINAZOLINYL)-4-(1- PIPERIDINYL)-, HYDRATE (1:1), (2E)-

Common Name

English

PF-00299804-03

Code

English

Dacomitinib monohydrate [WHO-DD]

Common Name

English

VIZIMPRO

Brand Name

English

(2E)-N-(4-(3-CHLORO-4-FLUOROPHENYL)AMINO)7-METHOXYQUINAZOLIN-6-YL)4-(PIPERIDIN-1-YL)BUT-2-ENAMIDE MONOHYDRATE

Common Name

English

DACOMITINIB [MI]

Common Name

English

Classification Tree Code System Code

WHO-ATC

L01XE47